Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: Results from a nationwide cohort in Nigeria

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Oladimeji, Olanrewaju ^a,b   Isaakidis, Petros ^c   Obasanya, Olusegun J ^d   Eltayeb, Osman ^e   Khogali, Mohammed ^c   Van Den Bergh, Rafael ^c   Kumar, Ajay M V ^f   Hinderaker, Sven Gudmund ^g   Abdurrahman, Saddiq T ^h   Lawson, Lovett ^a   Cuevas, Luis E ^b  

^a ZANKLI MEDICAL CENTRE   (Nigeria)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d Federal Ministry of Health   (Nigeria)

^e Damien Foundation Belgium   (Nigeria)

^f INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^g UNIVERSITY OF BERGEN   (Norway)

^h National Tuberculosis and Leprosy Control Programme   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; COTRIMOXAZOLE; CYCLOSERINE; KANAMYCIN; LEVOFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DIET SUPPLEMENTATION; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NIGERIA; OUTCOME ASSESSMENT; PSYCHOSOCIAL CARE; RETROSPECTIVE STUDY; SPUTUM SMEAR; SURVIVAL; UNDERWEIGHT; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NIGERIA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84899528808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094393     Document Type: Article

References (27)

1. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G (2007) Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 196 (3): S482-490. (Pubitemid 351417242)
2. World Health Organization (WHO) (2012) Multidrug and extensively drug resistant TB (M/XDR-TB): 2012 global report on surveillance and response (WHO/HTM/TB/2010.3). Geneva.
3. Federal Ministry of Health, Nigeria (FMOH) (2012) National Drug Resistance TB Prevalence Survey Report August 2012.
4. World Health Organization (WHO) (2013) Multidrug and extensively drug resistant TB (M/XDR-TB): 2013 global report.
5. United States Agency International Development (2013) Available at http://www.tbcare1.org/countries/africa/nia/.Accessed November 25, 2013.
6. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, et al. (2012) Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Med 9(8): e1001300.
7. Hafkin J, Modongo C, Newcomb C, Lowenthal (2013)Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.DOI http://dx.doi.org/10.5588/ijtld.12.0100.
8. James C, Brust M, Lygizos M, Chaiyachati K (2011)Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa.
9. Brust J, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, et al. (2010) Culture Conversion among HIV Co-infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLoS ONE 6(1): 6:e15841.
10. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348:119-128. (Pubitemid 36056718)
11. National Tuberculosis and Leprosy Control Workers Manual, Ministry of Health Nigeria 5th edition (2010) Available athttp://www.who.int/hiv/pub/ guidelines/nigeria-tb.pdf. Accessed November 25, 2013.
12. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 Update. Geneva.
13. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM (2009) Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. PLoS ONE 4(9): e6914.
14. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. (2009)Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9: 153-161.
15. Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E, et al. (2011) Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patientsin a Slum Setting in Mumbai, India. Plos ONE 6(12): e28066.
16. World Health Organization (WHO) (2009) Management of MDR-TB: a field guide. A companion document to Guidelines for the Programmatic Management of Drug-resistant Tuberculosis (WHO/HTM/TB/2008.402a). Geneva.
17. Heller T, Lessells R, Wallrauch C, Bärnighausen T, Cooke GS, et al. (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 14: 420-6.
18. Shin S, Furin J, Bayona J, Mate K, Kim JY, et al. (2004) Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc. Sci. Med 59: 1529-1539. (Pubitemid 38891418)
19. Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, et al. (2006)Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 3: e352
20. Jenkins HE,-Ciobanu A,-Plesca V,-Crudu V,-Galusca I, et al. (2013) Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. Int J Tuberc Lung Dis.17(3):373-80. doi: 10.5588/ijtld.12.0464.
21. Chadha SS, Sharath BN, Reddy K (2011) Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLoS ONE; 6: e26659.
22. Harries AD, Michongwe J, Nyirenda TE (2004) Using a bus service for transporting sputum specimens to the Central Reference Laboratory: effect on the routine TB culture service in Malawi. Int J Tuberc Lung Dis; 8: 204-210. (Pubitemid 38622928)
23. Khann S, Mao ET, Rajendra YP, Satyanarayana S, Nagaraja SB, et al. (2013) Linkage of presumptive multidrug resistant tuberculosis (MDR-TB) patients to diagnostic and treatment services in Cambodia. PLoS ONE; 8: e59903.
24. Qi W, Harries AD, Hinderaker SG (2011) Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China. Int J Tuberc Lung Dis; 15: 137-139.
25. Kilale AM, Ngowi BJ, Mfinanga GS (2013)Are sputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. Public Health Action; 3: 156-159.
26. Raguenaud ME, Isaakidis P, Zachariah R, Te V, Soeung S, et al. (2009) Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatrics 9:54.
27. Isaakidis P, Paryani R, Khan S, Mansoor H, Manglani M, et al. (2013) Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India. PLoS ONE 8(7): e68869